Furosemide

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Furosemide
Generic name
FUROSEMIDE
Manufacturer
AvKARE
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
d4c532be-1f3f-60d3-e053-2995a90a98be
SPL ID
485d7945-6751-e159-e063-6294a90a27ce
Version
3
Effective date
2026-01-14
Source export date
2026-09-28
Source partition
10
Source file
https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-09-28/4bbc9760f647649b787710953d978bd6419e899ba8b90f32c3d972aae43947f8/drug-label-0010-of-0014.json.zip
Source manifest SHA-256
cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
Import run
20260929T050834Z
Imported at
2026-09-29 06:08:16
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 2 matching rows.

warnings

WARNING Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION ).

warnings

WARNINGS In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) (see PRECAUTIONS: Drug Interactions ).

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 2 · 7 matching rows.

adverse reactions

ADVERSE REACTIONS Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions 1. hepatic encephalopathy in patients with hepatocellular insufficiency 6. oral and gastric irritation 7. cramping 2. pancreatitis 8. diarrhea 3. jaundice (intrahepatic cholestatic jaundice) 9. constipation 4. increased liver enzymes 10. nausea 5. anorexia 11. vomiting Systemic Hypersensitivity Reactions 1. severe anaphylactic or anaphylactoid reactions (e.g., with shock) 3. interstitial nephritis 2. systemic vasculitis 4. necrotizing angiitis Central Nervous System Reactions 1. tinnitus and hearing loss 5. headache 2. paresthesias 6. blurred vision 3. vertigo 7. xanthopsia 4. dizziness Hematologic Reactions 1. aplastic anemia 5. leukopenia 2. thrombocytopenia 6. anemia 3. agranulocytosis 7. eosinophilia 4. hemolytic anemia Dermatologic-Hypersensitivity Reactions 1. toxic epidermal necrolysis 7. bullous pemphigoid 2. Stevens-Johnson Syndrome 8. purpura 3. erythema multiforme 9. fever 4. drug rash with eosinophilia and systemic symptoms 10. rash 5. acute generalized exanthematous pustulosis 11. pruritus 6. exfoliative dermatitis 12. urticaria Cardiovascular Reaction Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics. Increase in cholesterol and triglyceride serum levels Other Reactions 1. hyperglycemia 6. restlessness 2. glycosuria 7. urinary bladder spasm 3. hyperuricemia 8. thrombophlebitis 4. muscle spasm 9. fever 5. weakness Whenever adverse reactions are moderate or severe, furosemide dosage should be reduced or therapy withdrawn. To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-855-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

adverse reactions table

<table width="100%"><colgroup><col width="50%"/><col width="50%"/></colgroup><tbody><tr><td rowspan="2" valign="top"><list listType="ordered"><item>1. hepatic encephalopathy in patients with hepatocellular insufficiency</item></list></td><td valign="top"><list listType="ordered"><item>6. oral and gastric irritation</item></list></td></tr><tr><td valign="top"><list listType="ordered"><item>7. cramping</item></list></td></tr><tr><td valign="top"><paragraph>2. pancreatitis</paragraph></td><td valign="top"><paragraph>8. diarrhea</paragraph></td></tr><tr><td valign="top"><list listType="ordered"><item>3. jaundice (intrahepatic cholestatic jaundice)</item></list></td><td valign="top"><paragraph>9. constipation</paragraph></td></tr><tr><td valign="top"><paragraph>4. increased liver enzymes</paragraph></td><td valign="top"><paragraph>10. nausea</paragraph></td></tr><tr><td valign="top"><paragraph>5. anorexia</paragraph></td><td valign="top"><list listType="ordered"><item>11. vomiting</item></list></td></tr></tbody></table>

adverse reactions table

<table width="100%"><colgroup><col width="50%"/><col width="50%"/></colgroup><tbody><tr><td valign="top"><list listType="ordered"><item>1. severe anaphylactic or anaphylactoid reactions (e.g., with shock)</item></list></td><td valign="top"><paragraph>3. interstitial nephritis</paragraph></td></tr><tr><td valign="top"><list listType="ordered"><item>2. systemic vasculitis</item></list></td><td valign="top"><paragraph>4. necrotizing angiitis</paragraph></td></tr></tbody></table>

adverse reactions table

<table width="100%"><colgroup><col width="50%"/><col width="50%"/></colgroup><tbody><tr><td valign="top"><paragraph>1. tinnitus and hearing loss</paragraph></td><td valign="top"><paragraph>5. headache</paragraph></td></tr><tr><td valign="top"><paragraph>2. paresthesias</paragraph></td><td valign="top"><paragraph>6. blurred vision</paragraph></td></tr><tr><td valign="top"><paragraph>3. vertigo</paragraph></td><td valign="top"><paragraph>7. xanthopsia</paragraph></td></tr><tr><td valign="top"><paragraph>4. dizziness</paragraph></td><td valign="top"/></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.